Stroke survivors living in areas with poor economic conditions were twice as likely to have a poor recovery compared to survivors living in areas with better conditions, according to a preliminary study to be presented at the American Stroke Association’s International Stroke Conference 2024.
Swiss biotech unloads US rights to Duchenne candidate for $231M
Santhera, a Swiss biotech waiting to see if the FDA will approve its steroid vamorolone for patients with Duchenne muscular dystrophy in the fall, is
June 21, 2023